FDA Approves Encelto, First Treatment for Macular Telangiectasia Type 2
Overview
The FDA has approved Encelto, an ocular insert delivering ciliary neurotrophic factor, as the first treatment for Macular Telangiectasia type 2 (MacTel). Clinical trials demonstrated that Encelto significantly slows macular photoreceptor loss over 24 months, offering hope for patients with this progressive retinal disease.
Background
Macular Telangiectasia type 2 (MacTel) is a rare, progressive neurodegenerative retinal disease causing central vision loss, typically developing in middle-aged adults. There is currently no cure or FDA-approved treatment for MacTel, which affects approximately 0.1% of the US population, or about 250,000 people. Worldwide, an estimated 2 million individuals are affected. Encelto (revakinagene taroretcel-lwey) is an encapsulated cell therapy implanted in the vitreous to deliver sustained doses of ciliary neurotrophic factor (CNTF) to the retina, aiming to slow disease progression.
Data Highlights
| Trial | Phase | Outcome |
|---|---|---|
| NTMT-02 | 2 | Demonstrated safety and efficacy |
| NTMT-03A and NTMT-03B | 3 | Significant slowing of macular photoreceptor loss over 24 months |
Key Findings
- Encelto is the first FDA-approved treatment for MacTel.
- It is an ocular insert delivering ciliary neurotrophic factor directly to the retina.
- Phase 3 trials showed significant slowing of macular photoreceptor loss over 24 months.
- Encelto was shown to be safe and effective in phase 2 and phase 3 studies.
- MacTel affects approximately 0.1% of the US population, with no prior approved treatments.
- Encelto is expected to be available in the US by June 2025.
Clinical Implications
Encelto offers a novel therapeutic option to slow vision loss in patients with MacTel, a disease previously lacking approved treatments. Clinicians should consider this treatment for eligible patients to potentially delay disease progression and preserve central vision. Early identification and referral for Encelto implantation may improve long-term visual outcomes.
Conclusion
The FDA approval of Encelto marks a significant advancement in managing MacTel by providing the first treatment to slow retinal degeneration. This development offers new hope for patients facing progressive vision loss from this rare disease.
References
- Neurotech Pharmaceuticals/2024 -- FDA Approves First Treatment for Macular Telangiectasia Type 2
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.